Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Representative Results
  • Discussion
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

This protocol provides reliable methods of solid tumor dissociation and myeloid cell isolation in murine intradermal or subcutaneous tumor models. Flow cytometry allows for phenotypic characterization of heterogeneous myeloid populations within the tumor microenvironment and sorting will demonstrate their functionality in the context of adoptive transfer.

Abstract

The tumor-infiltrating myeloid cell compartment represents a heterogeneous population of broadly immunosuppressive cells that have been exploited by the tumor to support its growth. Their accumulation in tumor and secondary lymphoid tissue leads to the suppression of antitumor immune responses and is thus a target for therapeutic intervention. As it is known that the local cytokine milieu can dictate the functional programming of tumor-infiltrating myeloid cells, strategies have been devised to manipulate the tumor microenvironment (TME) to express a cytokine landscape more conducive to antitumor myeloid cell activity. To evaluate therapy-induced changes in tumor-infiltrating myeloid cells, this paper will outline the procedure to dissociate intradermal/subcutaneous tumor tissue from solid tumor-bearing mice in preparation for leukocyte recovery. Strategies for flow cytometric analysis will be provided to enable the identification of heterogeneous myeloid populations within isolated leukocytes and the characterization of unique myeloid phenotypes. Lastly, this paper will describe a means of purifying viable myeloid cells for functional assays and determining their therapeutic value in the context of adoptive transfer.

Introduction

The tumor microenvironment (TME) is comprised of rapidly proliferating neoplastic cells and a surrounding heterogeneous stromal cell compartment. As growing tumors are often poorly vascularized, the TME is a peripheral site uniquely characterized by hypoxia, nutrient deprivation, and acidosis1. To survive in this landscape, tumor stress responses and metabolic reprogramming result in the secretion of soluble factors that promote tissue remodeling and angiogenesis as well as the selective recruitment of immune cells2. As myeloid cells are one of the most abundant type of hematopoietic cells in the TME, there is increasing....

Protocol

NOTE: All animal studies complied with the Canadian Council on Animal Care guidelines and were approved by McMaster University's Animal Research Ethics Board.

1. Tumor harvest and dissociation

  1. Inoculate 6-8-week-old, female, C57BL/6 mice intradermally/subcutaneously with 2 × 105 B16 melanoma cells as described by Nguyen et al.8 Allow tumors to grow for 7 days before harvesting.
  2. Euthanize the mouse by cervical dislo.......

Representative Results

The results demonstrate that this method produces a high yield of myeloid cells from solid murine tumors. The preservation of receptor integrity and cellular viability facilitates reliable functional analysis of the desired myeloid subsets. These improvements to myeloid cell isolation allowed the discernment of the changing function of intratumoral myeloid cells upon normalization of the TME with the class I histone deacetylase inhibitor (HDACi), MS-275, during adoptive T cell therapy. TIL isolation protocols typically d.......

Discussion

Although tumor-infiltrating myeloid cells exist in varying activation and differentiation states within the tumor, several subsets have been identified including tumor-associated DCs (TADCs), tumor-associated neutrophils (TANs), myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs)12. Unfortunately, the overlapping expression of cell-surface markers used to identify these myeloid cell subsets makes it currently challenging to phenotypically differentiate tumor myeloid c.......

Acknowledgements

This work was supported by the Ontario Institute for Cancer Research through funding provided by the Government of Ontario, as well as the Canadian Institutes of Health Research (FRN 123516 and FRN 152954), the Canadian Cancer Society (grant 705143), and the Terry Fox Research Institute (TFRI-1073).

....

Materials

NameCompanyCatalog NumberComments
Alexa Fluor 700 Mouse Anti-Mouse CD45.2BD Biosciences5606931:100
APC-Cy7 Mouse Anti-Mouse NK-1.1BD Biosciences5606181:100
Biotin Mouse Anti-Mouse CD45.2BD Biosciences553771
BV421 Hamster Anti-Mouse CD11cBD Biosciences5627821:100
BV650 Rat Anti-Mouse F4/80BD Biosciences7432821:100
BV711 Rat Anti-Mouse CD8aBD Biosciences5630461:100
Collagenase, Type IV, powderGibco17104019
DNase IRoche10104159001
EasySep Mouse CD11b Positive Selection Kit IIStemcell technologies18970
EasySep Mouse CD11c Positive Selection Kit IIStemcell technologies18780
EasySep Release Mouse Biotin Positive Selection KitStemcell technologies17655
FITC Rat Anti-Mouse Ly-6CBD Biosciences5531041:100
Fixable Viability Stain 510BD Biosciences5644061:1000
Fixation/Permeabilization Solution Kit (BD Cytofix/Cytoperm)BD Biosciences554714
PE Rat Anti-CD11bBD Biosciences5573971:100
PE-Cy7 Rat Anti-Mouse CD4BD Biosciences5527751:100
PerCP-Cy5.5 Rat Anti-Mouse Ly-6GBD Biosciences5606021:100
Perm/Wash (BD Perm/Wash)BD Biosciences554723
Purified Rat Anti-Mouse CD16/CD32 (Mouse BD Fc Block)BD Biosciences553141
iNOS Monoclonal Antibody (CXNFT), APCThermo Fisher17-5920-821:100
Human/Mouse Arginase 1/ARG1 Fluorescein-conjugated AntibodyR&D SystemsIC5868F1:100

References

  1. Paardekooper, L. M., Vos, W., vanden Bogaart, G. Oxygen in the tumor microenvironment: effects on dendritic cell function. Oncotarget. 10 (8), 883-896 (2019).
  2. Schouppe, E., De Baetselier, P., Van Ginderachter, J. A., Sarukhan, A.

Explore More Articles

Tumor infiltrating Myeloid CellsFlow CytometryAdoptive TransferTumor MicroenvironmentLeukocyte RecoveryMyeloid PhenotypesFunctional Assays

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved